Patents by Inventor Dinah W. Y. Sah
Dinah W. Y. Sah has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Patent number: 9574191Abstract: The present invention relates to the selective inhibition of protein expression of CAG repeat-related disease proteins such as Huntingtin Disease Protein and Ataxin-3 using double-stranded RNAs and nucleic acid analogs. Chemically-modified RNAs having at least one mismatch as compared to the target CAG repeat sequence are specifically contemplated.Type: GrantFiled: February 3, 2011Date of Patent: February 21, 2017Assignee: THE BOARD OF REGENTS OF THE UNIVERSITY OF TEXAS SYSTEMInventors: David R. Corey, Jiaxin Hu, Dinah W. Y. Sah
-
Publication number: 20150224213Abstract: This invention provides treatment compositions as well as systems and methods of determining and administering an effective amount of treatment for a neurological disorder. The treatment composition can contain a labeled interfering RNA (iRNA) agent capable of decreasing expression of a target RNA associated with the neurological disorder. The methods of the invention include determining an effective amount of a therapeutic composition by introducing a solution containing a tracer into the brain of a mammal. The tracing solution is monitored until a target volume of distribution at steady state distribution is substantially achieved, and the rate of delivery of the therapeutic composition is determined. The therapeutic composition can then be administered at the rate determined by use of the tracing solution.Type: ApplicationFiled: February 12, 2015Publication date: August 13, 2015Inventors: Dinah W.Y. SAH, Andrei P. Guzaev, Matthew H. Adams, Pei Ge, Muthiah Manoharan, Douglas Ulen Gwost, Gregory Robert Stewart, David Kent Stiles, Brian Dale Nelson, William Frederick Kaemmerer, Don Marshall Gash
-
Patent number: 8957038Abstract: This invention provides treatment compositions as well as systems and methods of determining and administering an effective amount of treatment for a neurological disorder. The treatment composition can contain a labeled interfering RNA (iRNA) agent capable of decreasing expression of a target RNA associated with the neurological disorder. The methods of the invention include determining an effective amount of a therapeutic composition by introducing a solution containing a tracer into the brain of a mammal. The tracing solution is monitored until a target volume of distribution at steady state distribution is substantially achieved, and the rate of delivery of the therapeutic composition is determined. The therapeutic composition can then be administered at the rate determined by use of the tracing solution.Type: GrantFiled: July 15, 2010Date of Patent: February 17, 2015Assignee: Medtronic, Inc.Inventors: Dinah W. Y. Sah, Andrei P. Guzaev, Matthew H. Adams, Pei Ge, Muthiah Manoharan, Douglas Ulen Gwost, Gregory Robert Stewart, David Kent Stiles, Brian Dale Nelson, William Frederick Kaemmerer, Don Marshall Gash
-
Publication number: 20140349930Abstract: The invention relates to treatments of neuropathic pain, including tactile allodynia, and to treatments for reducing loss of pain sensitivity associated with neuropathy. The present treatments involve the use of neublastin (NBN) polypeptides.Type: ApplicationFiled: November 12, 2013Publication date: November 27, 2014Applicant: BIOGEN IDEC MA INC.Inventor: Dinah W. Y. Sah
-
Publication number: 20130172399Abstract: The present invention relates to the selective inhibition of protein expression of CAG repeat-related disease proteins such as Huntingtin Disease Protein and Ataxin-3 using double-stranded RNAs and nucleic acid analogs. Chemically-modified RNAs having at least one mismatch as compared to the target CAG repeat sequence are specifically contemplated.Type: ApplicationFiled: February 3, 2011Publication date: July 4, 2013Inventors: David R. Corey, Jiaxin Hu, Dinah W.Y. Sah
-
Publication number: 20130130981Abstract: The invention relates to treatments of neuropathic pain, including tactile allodynia, and to treatments for reducing loss of pain sensitivity associated with neuropathy. The present treatments involve the use of neublastin (NBN) polypeptides.Type: ApplicationFiled: September 4, 2012Publication date: May 23, 2013Applicant: BIOGEN IDEC MA INC.Inventor: Dinah W. Y. Sah
-
Publication number: 20130109624Abstract: The invention relates to neublastin neurotrophic factor polypeptides, nucleic acids encoding neublastin polypeptides, and antibodies that bind specifically to neublastin polypeptides, as well as methods of making and methods of using the same.Type: ApplicationFiled: June 27, 2012Publication date: May 2, 2013Applicants: NSGENE A/S, BIOGEN IDEC MA INC.Inventors: Dinah W.Y. Sah, Teit E. Johansen, Anthony Rossomando
-
Patent number: 8217146Abstract: The invention relates to neublastin neurotrophic factor polypeptides, nucleic acids encoding neublastin polypeptides, and antibodies that bind specifically to neublastin polypeptides, as well as methods of making and methods of using the same.Type: GrantFiled: December 7, 2009Date of Patent: July 10, 2012Assignees: Biogen Idec MA Inc., NsGene A/SInventors: Dinah W. Y. Sah, Teit E. Johansen, Anthony Rossomando
-
Publication number: 20120116360Abstract: This invention provides treatment compositions as well as systems and methods of determining and administering an effective amount of treatment for a neurological disorder. The treatment composition can contain a labeled interfering RNA (iRNA) agent capable of decreasing expression of a target RNA associated with the neurological disorder. The methods of the invention include determining an effective amount of a therapeutic composition by introducing a solution containing a tracer into the brain of a mammal. The tracing solution is monitored until a target volume of distribution at steady state distribution is substantially achieved, and the rate of delivery of the therapeutic composition is determined. The therapeutic composition can then be administered at the rate determined by use of the tracing solution.Type: ApplicationFiled: July 15, 2010Publication date: May 10, 2012Applicants: Alnylam Pharmaceuticals, Inc., Medtronic, Inc.Inventors: Dinah W. Y. Sah, Andrei P. Guzaev, Matthew H. Adams, Pei Ge, Muthiah Manoharan, Douglas Ulen Gwost, Gregory Robert Stewart, David Kent Stiles, Brian Dale Nelson, William Frederick Kaemmerer, Don Marshall Gash
-
Publication number: 20120083453Abstract: The invention relates to treatments of neuropathic pain, including tactile allodynia, and to treatments for reducing loss of pain sensitivity associated with neuropathy. The present treatments involve the use of neublastin (NBN) polypeptides.Type: ApplicationFiled: January 24, 2011Publication date: April 5, 2012Applicant: BIOGEN IDEC MA INC.Inventor: Dinah W.Y. Sah
-
Patent number: 8030456Abstract: Disclosed are immunogenic Nogo receptor-1 polypeptides, Nogo receptor-1 antibodies, antigen-binding fragments thereof, soluble Nogo receptors and fusion proteins thereof and nucleic acids encoding the same. Also disclosed are compositions comprising, and methods for making and using, such Nogo receptor antibodies, antigen-binding fragments thereof, soluble Nogo receptors and fusion proteins thereof and nucleic acids encoding the same.Type: GrantFiled: December 15, 2008Date of Patent: October 4, 2011Assignees: Yale University, Biogen Idec MA Inc.Inventors: Daniel H. S. Lee, R. Blake Pepinsky, Weiwei Li, Jane K. Relton, Dane S. Worley, Stephen M. Strittmatter, Dinah W. Y. Sah, Sylvia A. Rabacchi
-
Publication number: 20110129477Abstract: The invention relates generally to genes that encode proteins that inhibit axonal growth. The invention relates specifically to genes encoding NgR protein homologs in humans and mice. The invention also includes compositions and methods for modulating the expression and activity of Nogo and the NgR proteins. Specifically, the invention includes peptides, proteins and antibodies that block Nogo-mediated inhibition of axonal extension. The compositions and methods of the invention are useful in the treatment of cranial or cerebral trauma, spinal cord injury, stroke or a demyelinating disease.Type: ApplicationFiled: November 23, 2010Publication date: June 2, 2011Inventors: Stephen M. STRITTMATTER, Richard L. Cate, Dinah W.Y. Sah
-
Publication number: 20100292142Abstract: The invention relates to neublastin neurotrophic factor polypeptides, nucleic acids encoding neublastin polypeptides, and antibodies that bind specifically to neublastin polypeptides, as well as methods of making and methods of using the same.Type: ApplicationFiled: December 7, 2009Publication date: November 18, 2010Applicants: BIOGEN IDEC MA INC., NSGENE A/SInventors: Dinah W. Y. Sah, Teit E. Johansen, Anthony Rossomando
-
Patent number: 7655463Abstract: The invention relates to neublastin neurotrophic factor polypeptides, nucleic acids encoding neublastin polypeptides, and antibodies that bind specifically to neublastin polypeptides, as well as methods of making and methods of using the same.Type: GrantFiled: February 12, 2008Date of Patent: February 2, 2010Assignees: Biogen Idec MA Inc., NsGene A/SInventors: Dinah W. Y. Sah, Teit E. Johansen, Anthony Rossomando
-
Publication number: 20090258831Abstract: The invention relates to treatments of neuropathic pain, including tactile allodynia, and to treatments for reducing loss of pain sensitivity associated with neuropathy. The present treatments involve the use of neublastin (NBN) polypeptides.Type: ApplicationFiled: March 6, 2009Publication date: October 15, 2009Applicant: Biogen Idec MA Inc.Inventor: Dinah W.Y. Sah
-
Publication number: 20090215691Abstract: Disclosed are immunogenic Nogo receptor-1 polypeptides, Nogo receptor-1 antibodies, antigen-binding fragments thereof, soluble Nogo receptors and fusion proteins thereof and nucleic acids encoding the same. Also disclosed are compositions comprising, and methods for making and using, such Nogo receptor antibodies, antigen-binding fragments thereof, soluble Nogo receptors and fusion proteins thereof and nucleic acids encoding the same.Type: ApplicationFiled: December 15, 2008Publication date: August 27, 2009Applicants: Yale University, Biogen Idec MA Inc.Inventors: Daniel H.S. Lee, R. Blake Pepinsky, Weiwei Li, Jane K. Relton, Dane S. Worley, Stephen M. Strittmatter, Dinah W.Y. Sah, Sylvia A. Rabacchi
-
Publication number: 20090053229Abstract: The invention provides methods for treating conditions of the eye involving death or degeneration of retinal ganglion cells, including glaucoma, by the administration of Nogo receptor-1 antagonists.Type: ApplicationFiled: May 12, 2006Publication date: February 26, 2009Inventors: Daniel H.S. Lee, Dinah W.Y. Sah, Kwok Fai So, Wutian Wu
-
Patent number: 7465705Abstract: Disclosed are immunogenic Nogo receptor-1 polypeptides, Nogo receptor-1 antibodies, antigen-binding fragments thereof, soluble Nogo receptors and fusion proteins thereof and nucleic acids encoding the same. Also disclosed are compositions comprising, and methods for making and using, such Nogo receptor antibodies, antigen-binding fragments thereof, soluble Nogo receptors and fusion proteins thereof and nucleic acids encoding the same.Type: GrantFiled: February 10, 2005Date of Patent: December 16, 2008Assignees: Yale University, Biogen Idec MA Inc.Inventors: Daniel H. S. Lee, R. Blake Pepinsky, Weiwei Li, Jane K. Relton, Dane S. Worley, Stephen M. Strittmatter, Dinah W. Y. Sah, Sylvia A. Rabacchi
-
Patent number: 7456255Abstract: The invention relates generally to genes that encode proteins that inhibit axonal growth. The invention relates specifically to genes encoding NgR protein homologs in humans and mice. The invention also includes compositions and methods for modulating the expression and activity of Nogo and the NgR proteins. Specifically, the invention includes peptides, proteins and antibodies that block Nogo-mediated inhibition of axonal extension. The compositions and methods of the invention are useful in the treatment of cranial or cerebral trauma, spinal cord injury, stroke or a demyelinating disease.Type: GrantFiled: October 6, 2006Date of Patent: November 25, 2008Assignees: Yale University, Biogen Idec MA Inc.Inventors: Stephen Strittmatter, Richard L. Cate, Dinah W. Y. Sah
-
Publication number: 20080274112Abstract: Disclosed are immunogenic Nogo receptor-1 polypeptides, Nogo receptor-1 antibodies, antigen-binding fragments thereof, soluble Nogo receptors and fusion proteins thereof and nucleic acids encoding the same. Also disclosed are compositions comprising, and methods for making and using, such Nogo receptor antibodies, antigen-binding fragments thereof, soluble Nogo receptors and fusion proteins thereof and nucleic acids encoding the same.Type: ApplicationFiled: January 30, 2004Publication date: November 6, 2008Inventors: Daniel H.S. Lee, R. Blake Pepinsky, Weiwei Li, Sylvia A. Rabacchi, Jane K. Relton, Dane S. Worley, Stephen M. Strittmatter, Dinah W.Y. Sah